Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HLCS | P50747 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 5/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | PRKCH | P24723 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20448811 | 0.98 | CYP1A2 (0.39) | CYP1A2ALDH1A1HLCSL3MBTL1MEN1 | |
| SCHEMBL2007688 | 0.98 | CYP1A2 (0.39) | CYP1A2ALDH1A1HLCSL3MBTL1MEN1 | |
| SCHEMBL7659302 | 0.94 | ALDH1A1 (0.40) | CYP1A2ALDH1A1HLCSL3MBTL1MEN1 | |
| SCHEMBL7662496 | 0.86 | SMN1; SMN2 (0.34) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL7710744 | 0.81 | TERT (0.38) | — | |
| SCHEMBL31055607 | 0.81 | TERT (0.38) | — | |
| SCHEMBL762450 | 0.77 | — | — | |
| SCHEMBL8647164 | 0.77 | TDP1 (0.45) | ALDH1A1L3MBTL1MEN1KMT2APKM | |
| SCHEMBL12344227 | 0.77 | — | — | |
| SCHEMBL9886349 | 0.75 | SMN1; SMN2 (0.41) | ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288269-A1 | PROCESS FOR THE PREPARATION OF RANDOM POLYPEPTIDES AND EMPLOYING CIRCULAR DICHROISM AS A GUIDANCE TOOL FOR THE MANUFACTURE OF GLATIRAMER ACETATE | BIOCON LTD (IN) | 2014-09-25 | — | — | US | disclosed |
| US-7205385-B2 | magnetic resonance imaging agents; poly(amino acid-imaging agent) product can be obtained in high purity without a rigorous purification since all impurities are removed at the monomer synthesis stage | GENERAL ELECTRIC COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1194147-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1194146-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1194146-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-6465497-B2 | SUBSTITUTED 5-ARYL-2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES; AGONISTS OF PPAR (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR); USEFUL TREATING DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND OBESITY | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1194146-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1194146-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6399640-B1 | ANTIDIABETIC AGENTS; ANTICHOLESTEROL AGENTS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| US-6399640-B1 | ANTIDIABETIC AGENTS; ANTICHOLESTEROL AGENTS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| US-6380191-B1 | FOR TREATMENT, CONTROL OR PREVENTION OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA (INCLUDING HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA), ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO. INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1194146-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1194146-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2000078312-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078312-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288269-A1 | PROCESS FOR THE PREPARATION OF RANDOM POLYPEPTIDES AND EMPLOYING CIRCULAR DICHROISM AS A GUIDANCE TOOL FOR THE MANUFACTURE OF GLATIRAMER ACETATE | QPCT, GLUL, ARGLU1 | CYP1A2 3145/4885ALDH1A1 4369/4885HLCS 337/4885 |
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | PPARD, PPARA, PPARG | CYP1A2 683/4885ALDH1A1 679/4885HLCS 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.